IVF Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -150.51% compared to INVO Fertility, Inc.'s net margin of -255.85%. INVO Fertility, Inc.'s return on equity of -471.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

INVO Fertility, Inc. has a consensus price target of --, signalling upside risk potential of 8680.49%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that INVO Fertility, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe INVO Fertility, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

INVO Fertility, Inc. has a beta of 2.540, which suggesting that the stock is 153.97% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

INVO Fertility, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. INVO Fertility, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

INVO Fertility, Inc. quarterly revenues are $1.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. INVO Fertility, Inc.'s net income of -$2.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, INVO Fertility, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INVO Fertility, Inc. is 0.03x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -150.51% compared to INVO Fertility, Inc.'s net margin of 13.19%. INVO Fertility, Inc.'s return on equity of -471.28% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

INVO Fertility, Inc. has a consensus price target of --, signalling upside risk potential of 8680.49%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that INVO Fertility, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe INVO Fertility, Inc. is more attractive than Protalix Biotherapeutics, Inc..

INVO Fertility, Inc. has a beta of 2.540, which suggesting that the stock is 153.97% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

INVO Fertility, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INVO Fertility, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

INVO Fertility, Inc. quarterly revenues are $1.8M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. INVO Fertility, Inc.'s net income of -$2.6M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, INVO Fertility, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INVO Fertility, Inc. is 0.03x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -150.51% compared to INVO Fertility, Inc.'s net margin of --. INVO Fertility, Inc.'s return on equity of -471.28% beat Palatin Technologies's return on equity of --.

INVO Fertility, Inc. has a consensus price target of --, signalling upside risk potential of 8680.49%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that INVO Fertility, Inc. has higher upside potential than Palatin Technologies, analysts believe INVO Fertility, Inc. is more attractive than Palatin Technologies.

INVO Fertility, Inc. has a beta of 2.540, which suggesting that the stock is 153.97% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

INVO Fertility, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INVO Fertility, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

INVO Fertility, Inc. quarterly revenues are $1.8M, which are larger than Palatin Technologies quarterly revenues of --. INVO Fertility, Inc.'s net income of -$2.6M is higher than Palatin Technologies's net income of --. Notably, INVO Fertility, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INVO Fertility, Inc. is 0.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -150.51% compared to INVO Fertility, Inc.'s net margin of --. INVO Fertility, Inc.'s return on equity of -471.28% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

INVO Fertility, Inc. has a consensus price target of --, signalling upside risk potential of 8680.49%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that INVO Fertility, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe INVO Fertility, Inc. is more attractive than Theriva Biologics, Inc..

INVO Fertility, Inc. has a beta of 2.540, which suggesting that the stock is 153.97% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

INVO Fertility, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INVO Fertility, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

INVO Fertility, Inc. quarterly revenues are $1.8M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. INVO Fertility, Inc.'s net income of -$2.6M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, INVO Fertility, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INVO Fertility, Inc. is 0.03x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.